Observational studyFuture oncology (London, England)2021
Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.
Abstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Future oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 8 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- Pooled it
- Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.Virology journal · 2022Pooled it
- Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Pooled it
- Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Pooled it
- Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.European journal of cancer (Oxford, England : 1990) · 2022Pooled it
- COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety.Frontiers in endocrinology · 2022Pooled it
- Immune Response to an Inactivated Vaccine of SARS-CoV-2 (CoronaVac) in an Indigenous Brazilian Population: A Cohort Study.Vaccines · 2024Article
- Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer.Frontiers in public health · 2023Observational
- Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers.Clinical lung cancer · 2023Article
- Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.Trends in molecular medicine · 2022Review
- CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2.Human vaccines & immunotherapeutics · 2022Review
- COVID-19 in patients with gastrointestinal stromal tumors: Recommendations for management and vaccination.World journal of gastrointestinal pathophysiology · 2022Review
- Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.Journal of medical virology · 2022Article
- COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.Nature reviews. Clinical oncology · 2022Review
- Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.Journal of hematology & oncology · 2022Article
- COVID-19 vaccination in cancer patients: a narrative review.The Journal of international medical research · 2022Review
- Review
- Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Cengiz KaracinDepartment of Medical Oncology, Recep Tayyip Erdogan University Training & Research Hospital, Rize, Turkey.ORCID 0000-0002-7310-9328
Tulay ErenDepartment of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.ORCID 0000-0002-0088-1149
Esra ZeynelgilDepartment of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.ORCID 0000-0001-7200-9440
Goksen Inanc ImamogluDepartment of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.ORCID 0000-0003-0356-0727
Mustafa AltinbasDepartment of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.ORCID 0000-0002-8024-2362
Ibrahim KaradagDepartment of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.ORCID 0000-0002-2356-6790
Fatma Bugdayci BasalDepartment of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.ORCID 0000-0003-3562-2670
Irem BilgetekinDepartment of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.ORCID 0000-0003-1154-5850
Osman SutcuogluDepartment of Medical Oncology, Gazi University, Ankara, Turkey.ORCID 0000-0003-3835-2741
Ozan YaziciDepartment of Medical Oncology, Gazi University, Ankara, Turkey.ORCID 0000-0003-0038-3569
Nuriye OzdemirDepartment of Medical Oncology, Gazi University, Ankara, Turkey.ORCID 0000-0002-9235-9592
Ahmet OzetDepartment of Medical Oncology, Gazi University, Ankara, Turkey.ORCID 0000-0001-8731-9636
Yesim YildizDepartment of Infectious Diseases & Clinical Microbiology, Gazi University, Ankara, Turkey.ORCID 0000-0003-3006-4112
Selin Akturk EsenDepartment of Medical Oncology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.ORCID 0000-0002-3426-9505
Gokhan UcarDepartment of Medical Oncology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.ORCID 0000-0002-7649-1075
Dogan UncuDepartment of Medical Oncology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.ORCID 0000-0002-0929-3271
Bedia DincDepartment of Medical Microbiology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.ORCID 0000-0001-8318-2556
Musa Baris AykanDepartment of Medical Oncology, HSU Gulhane Training & Research Hospital, Ankara, Turkey.ORCID 0000-0001-7538-9119
İsmail ErturkDepartment of Medical Oncology, HSU Gulhane Training & Research Hospital, Ankara, Turkey.ORCID 0000-0001-6835-0988
Nuri KaradurmusDepartment of Medical Oncology, HSU Gulhane Training & Research Hospital, Ankara, Turkey.ORCID 0000-0003-3291-8062
Burak CivelekDepartment of Medical Oncology, A Life Hospital, Ankara, Turkey.ORCID 0000-0002-5627-599X
İsmail ÇelikDepartment of Preventive Oncology, Institute of Oncology, Hacettepe University, Ankara, Turkey.
Yakup ErgunDepartment of Medical Oncology, Batman Training & Research Hospital, Batman, Turkey.ORCID 0000-0003-4784-6743
Mutlu DoganDepartment of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.ORCID 0000-0001-9359-3770
Omur Berna OksuzogluDepartment of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.ORCID 0000-0002-2756-8646
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAged, 80 and overAntibodies, ViralAntineoplastic AgentsCOVID-19COVID-19 VaccinesDouble-Blind MethodFemaleHumansImmunogenicity, VaccineMaleMiddle AgedNeoplasmsProspective StudiesSARS-CoV-2Vaccines, InactivatedAntibodies, ViralAntineoplastic AgentsCOVID-19 VaccinesVaccines, InactivatedcancerchemotherapyCOVID-19immunogenicityimmunotherapymonoclonal antibodysafetytumorsvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.